NCT02041221View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Asthma
Interventions
DRUG

SPARC1316 Dose 1

The subjects will receive SPARC1316.

DRUG

Placebo

DRUG

SPARC1316 Dose 2

DRUG

SPARC1316 Dose 3

DRUG

SPARC1316 Dose 4

DRUG

SPARC1316 Dose 5

Trial Locations (1)

Unknown

SPARC study site, London

All Listed Sponsors
lead

Sun Pharma Advanced Research Company Limited

INDUSTRY

NCT02041221 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316 | Biotech Hunter | Biotech Hunter